Abstract Number: 2232 • 2016 ACR/ARHP Annual Meeting
Above-Label Dosing with Biologics in Treatment-NaïVe and Treatment-Experienced Patients with Moderate-to-Severe Psoriatic Arthritis
Title: Above-Label Dosing with Biologics in Treatment-Naïve and Treatment-Experienced Patients with Moderate-to-Severe Psoriatic Arthritis Authors: S. Schwartzman*1, Y. Li2, H. Zhou3, V. Herrera2, J. Palmer2…Abstract Number: 2233 • 2016 ACR/ARHP Annual Meeting
Predictors of Adherence and Costs in First and Second Years after Biologic Initiation in Patients with Rheumatoid Arthritis (RA)
Background/Purpose: Rheumatoid arthritis (RA) is a chronic disease requiring continuous therapy to reach low disease activity targets and to delay its long-term health effects.…Abstract Number: 2234 • 2016 ACR/ARHP Annual Meeting
Economic Impact of Above-Label Dosing with Biologics in Patients with Moderate-to-Severe Psoriatic Arthritis
Authors: S. Schwartzman*1, Y. Li2, H. Zhou3, V. Herrera2, J. Palmer2 Affiliations: 1Hospital for Special Surgery, New York, NY, US; 2Novartis Pharmaceuticals Corporation, East Hanover,…Abstract Number: 2235 • 2016 ACR/ARHP Annual Meeting
Utilization of Ambulatory Physician Encounters, Emergency Room Visits and Hospitalizations By RA Patients: A 13 Year Population Health Study
Background/Purpose: To determine total and subspecialty physician encounters, emergency room (ER) visits and hospitalizations in an incident cohort of rheumatoid arthritis (RA) cases and matched…Abstract Number: 2236 • 2016 ACR/ARHP Annual Meeting
Effects of Repository Corticotropin Injection on Medication Use in Patients with Rheumatologic Conditions: A Claims Data Study
Background/Purpose: Repository corticotropin injection (RCI) may produce anti-inflammatory and immune-modulatory effects. This study examined the demographics of those who used RCI and the trends in…Abstract Number: 2237 • 2016 ACR/ARHP Annual Meeting
Biologic DMARD Use Among U.S. Patients in an Online Rheumatoid Arthritis Community
Background/Purpose: Multiple biologic DMARDs (bDMARDs) are approved in the US for the treatment of RA. Previous studies have indicated significant clinical inertia in moving patients…Abstract Number: 2238 • 2016 ACR/ARHP Annual Meeting
RA Medication Preferences Among U.S. Patients in an Online Rheumatoid Arthritis Community
Background/Purpose: Medications used to manage RA vary in efficacy, safety, and convenience of use. A better understanding of patient preferences of these attributes is key…Abstract Number: 2239 • 2016 ACR/ARHP Annual Meeting
Patterns of Abatacept Utilization in Patients with Rheumatoid Arthritis. Have the Baseline Characteristics of These Patients Changed over Time?
Background/Purpose: Abatacept (ABA), a T cell co-stimulation inhibitor, was initially approved by the European Medicine Agency (EMA) for patients with rheumatoid arthritis (RA) who had…Abstract Number: 2240 • 2016 ACR/ARHP Annual Meeting
A Descriptive Analysis of Real-World Treatment Patterns in a Turkish Rheumatology Population That Continued Innovator Infliximab (Remicade) Therapy or Switched to Biosimilar Infliximab
Background/Purpose: This study examined treatment patterns in a rheumatology patient (pt) population initially prescribed innovator infliximab (IFX) that either switched to biosimilar infliximab (CT-P13) or…Abstract Number: 2241 • 2016 ACR/ARHP Annual Meeting
Health Economics of Uncontrolled Gout in the United States: A Systematic Literature Review
Background/Purpose: Gout is a crystal deposition disease and the most prevalent inflammatory arthritis in the United States (US). Maintaining gout control has been associated with…Abstract Number: 2242 • 2016 ACR/ARHP Annual Meeting
Comparison of Assessment and Management of RA and Other Rheumatic Diseases By Rheumatologists in Private Practices or an Academic Medical Center
Background/Purpose: Since 80% of rheumatologists practice outside the university setting, training projects for rheumatoid arthritis (RA) may benefit from an improved understanding of RA management…Abstract Number: 2243 • 2016 ACR/ARHP Annual Meeting
The Paucity of the Evidence Base for American College of Rheumatology Practice Guidelines
Background/Purpose: The American College of Rheumatology (ACR) practice guidelines establish U.S. and international treatment recommendations and hence performance measures and research priorities, so we sought…Abstract Number: 2244 • 2016 ACR/ARHP Annual Meeting
Utilization Patterns of Subcutaneously Administered Biologic Medications within a Sample of Rheumatoid Arthritis Patients
Background/Purpose: Adherence to medication is crucial to the maximum therapeutic benefit of biologic treatment. The plethora of currently approved biologic agents makes comparison…Abstract Number: 2245 • 2016 ACR/ARHP Annual Meeting
Injectable Corticosteroid Use in Musculoskeletal Care Specialties
Background/Purpose: Injectable corticosteroids (IC) are widely used for joint and soft tissue injections. Although four main types of preparations are available, there is sparse evidence…Abstract Number: 2246 • 2016 ACR/ARHP Annual Meeting
Glucocorticoids in Early Rheumatoid Arthritis Management, Friend or Foe?
Background/Purpose: ≥≥140/90 mmHg The only difference between treatments arms in either risk groups was a BMI decrease in Avant-Garde compared to Classic and Slim between baseline…
ACR Meeting Abstracts